share_log

Intuitive Surgical | 8-K: INTUITIVE ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2023 RESULTS

SEC announcement ·  Jan 9 13:00
Summary by Futu AI
Intuitive Surgical, Inc. (Intuitive) released unaudited preliminary financial results for the fourth quarter and full year of 2023 on January 9, 2024. The report highlighted a 21% growth in worldwide da Vinci procedures in Q4 2023 compared to Q4 2022, and a 22% increase for the full year. The company placed 415 da Vinci surgical systems in Q4, marking a 12% increase from the previous year, and 1,370 systems in 2023, up by 8% from 2022. Revenue for Q4 2023 is estimated at approximately $1.93 billion, a 17% rise from Q4 2022, with full-year revenue expected to be around $7.12 billion, representing a 14% increase. The growth in procedures and revenue was attributed to the adoption of the company's platforms and increased procedure volumes, particularly in U.S. general surgery and international cancer procedures. The report also noted a recovery in procedure...Show More
Intuitive Surgical, Inc. (Intuitive) released unaudited preliminary financial results for the fourth quarter and full year of 2023 on January 9, 2024. The report highlighted a 21% growth in worldwide da Vinci procedures in Q4 2023 compared to Q4 2022, and a 22% increase for the full year. The company placed 415 da Vinci surgical systems in Q4, marking a 12% increase from the previous year, and 1,370 systems in 2023, up by 8% from 2022. Revenue for Q4 2023 is estimated at approximately $1.93 billion, a 17% rise from Q4 2022, with full-year revenue expected to be around $7.12 billion, representing a 14% increase. The growth in procedures and revenue was attributed to the adoption of the company's platforms and increased procedure volumes, particularly in U.S. general surgery and international cancer procedures. The report also noted a recovery in procedure volumes following early 2023 COVID-19 resurgences in China. Intuitive's CEO, Gary Guthart, expressed satisfaction with the platform adoption and the company's focus on supporting customers' pursuit of the quadruple aim in acute interventions. The full financial results will be discussed in more detail during a conference call on January 23, 2024, following the company's presentation at the J.P. Morgan Healthcare Conference on January 10, 2024.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.